

**Question for written answer E-001288/2021
to the Commission**
Rule 138
Sara Cerdas (S&D)

Subject: Antimicrobial resistance and Europe's Beating Cancer Plan

Antibiotics are a key tool in cancer treatment plans. As cancer patients are more at risk of infection by multi-resistant organisms, effective antibiotics are essential to the success of these plans. Antibiotic resistance is a serious threat to these patients' survival and the likelihood of a good outcome in their treatment. In this context and in the light of the Beating Cancer Plan:

1. Will scientific research carried out within the framework of the Beating Cancer Plan take account of antimicrobials and how they affect cancer patients and survival rates?
2. What measures will the Commission propose with a view to tackling and mitigating the problem of multi-resistant micro-organism infections in cancer patients, and how will this be reflected in the Beating Cancer Plan?
3. With a view to improving both the exchange of information among Member States and the planning of specific action to take to tackle this threat, will the Commission bolster the EU AMR One Health Network?